Physician profile
Gloria E Dunkin
NPI 1316006703
$3,214.94
in general payments reported to CMS, 2019-2025
11 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $141 · 2021: $105 · 2022: $221 · 2023: $184 · 2024: $360 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,927 · Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,926.51 |
| Food and Beverage | $710.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,926.51 | 2025 | Deep Tms System |
| Alkermes, INC. | $361.96 | 2020-2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $238.72 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $238.15 | 2022-2024 | Vraylar |
| Gilead Sciences, INC. | $137.44 | 2023-2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $111.09 | 2019 | |
| Uswm, LLC | $103.77 | 2024 | Lucemyra |
| Janssen Pharmaceuticals, INC | $31.25 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $28.35 | 2025 | Auvelity |
| Indivior INC. | $22.95 | 2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Dunkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.